Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2002 Sep;110(6):743-5.
doi: 10.1172/JCI16568.

Cancer therapy and renal injury

Robert W Schrier  1
Affiliations
Comment

Cancer therapy and renal injury

Robert W Schrier. J Clin Invest. 2002 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Events proposed to cause nephrotoxic ARF. As indicated in the text, TNF-α participates in both an early, vascular phase and a later, proinflammatory phase in this response. Red arrows indicate points in the pathway where various protective therapies appear to interfere with nephrotoxicity.
See this image and copyright information in PMC

Comment on

References

    1. Safirstein, R.L. 2001. Renal diseases induced by anti-neoplastic agents. In Diseases of the kidney and urinary tract. R.W. Schrier, editor. Lippincott Williams and Wilkins. Philadelphia, Pennsylvania, USA. 1175–1188.
    1. Merouani A, Davidson SA, Schrier RW. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol. 1997;17:53–58. - PubMed
    1. Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int. 1996;50:1026–1031. - PubMed
    1. Parikh CR, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002;62:566–573. - PubMed
    1. Ramesh G, Reeves WB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxi-city. J Clin Invest. 2002;110:835–842. doi:10.1172/JCI200215606. - PMC - PubMed